Enterisol® Ileitis is the first live porcine vaccine in Australia. “We are pleased that Boehringer Ingelheim´s high quality standards in vaccine production complied with Australia’s highly demanding regulatory environment. We hope that many farmers can now benefit from the outstanding safety and efficacy of this innovative live vaccine” said Dr Hans-Juergen Leuchs, Member of the Board of Managing Directors at Boehringer Ingelheim.

Ileitis (porcine proliferative enteropathy) is a common enteric disease of pigs, which causes severe intestinal lesions, diarrhea and gut-bleedings which can negatively affect the growth performance in fattening due to reduced weight gain, extra feed costs in growing pigs and increased body weight variation at slaughter.

Ileitis is one of the most prevalent diseases worldwide which affects swine production. According to recent diagnostic surveys 1,2, in up to 90% of farms at least one pig was diagnosed to be infected by Lawsonia intracellularis.

With Ileitis-affected pigs which are poorly gaining weight, the farmer faces considerable economic losses. With the prevention of clinical signs of the infection and the improvement of economical factors (e.g. weight gain), the financial benefit for the farmer can even be as high as € 4 - 5 per slaughtered pig 3, 4. “Enterisol® Ileitis does not only make good economic sense, it is also an essential tool for the reduction of the total antibiotic use in pig farms” says Dr Hasenmaier, Head of Boehringer Ingelheim Animal Health GmbH.

In 2001, Enterisol® Ileitis has been launched in North America and has been licensed in three South-American countries, in nineteen European countries and in two Asian countries. Since 2001, more than 110 million pigs have been vaccinated worldwide, establishing Ileitis control as an essential part of professional pig health management.

Editorial Staff